1 / 38

17 June 2010 Opportunistic Infections H. Nina Kim, MD, MSc

17 June 2010 Opportunistic Infections H. Nina Kim, MD, MSc. Case 1. 43 yo man with HIV c/o bilateral R>L leg swelling and new lesion on his thigh. Has been feeling well, denies any fevers/nightsweats. ROS: Negative for cough/SOB, abd pain or change in stools. PMH: Stage 3 HIV, dx 1999

dong
Télécharger la présentation

17 June 2010 Opportunistic Infections H. Nina Kim, MD, MSc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 17 June 2010 Opportunistic Infections H. Nina Kim, MD, MSc

  2. Case 1 43 yo man with HIV c/o bilateral R>L leg swelling and new lesion on his thigh. Has been feeling well, denies any fevers/nightsweats. ROS: Negative for cough/SOB, abd pain or change in stools. PMH: Stage 3 HIV, dx 1999 Nadir CD4 45  current 158 cells/mm3 Hx Pneumocystis pneumonia in 1999 Hx oral candidiasis Current Meds: Truvada 1 tab PO qDay Kaletra 2 tabs PO BID TMP-SMX 1 DS tab PO qDay

  3. Physical Exam & Labs T 37.9°C HR 100 BP 130/69, RR 18 General – Fatigue-appearing man, no distress. HEENT – oral thrush. Chest – clear to auscultation. Cardiac – regular tachycardic, 2/6 systolic ejection murmur. ABD – normal bowel tones, no organomegaly, non-tender. Lymphatic – no adenopathy. Neuro – Alert, oriented x 4. O/W unremarkable. SKIN: … LAB: CD4 158. HIV RNA <30. Chemistries WNL including liver function panel.

  4. “Face of AIDS” • In 1981, emergence of KS among young gay men in New York, Los Angeles, San Francisco heralded start of AIDS epidemic • AIDS initially called “Kaposi’s Sarcoma & Opportunistic Infections” (KSOI) • Most common malignancy of AIDS patients • 20,000-fold higher risk to that of general population • 70-fold higher risk to that of other immunosuppressed groups

  5. Kaposi Sarcoma (KS) • Neoplasm • Skin • Mucous membranes • Lymphatic system • Viscera (pulmonary, GI tract) • Four variants • Classic KS (elderly men of E.Europe, Mediterranean descent) • Endemic African KS • Transplantation-related KS • Epidemic HIV-associated KS

  6. Kaposi Sarcoma (KS) • Histopathology • Dilated vessels, vascular slits • Spindle cells • RBCs, hemosiderin deposits • Inflammatory cells • Vascular hyperplasia or true neoplastic growth? • Monoclonal cancer  clonal outgrowth of spindle cells Johns Hopkins Autopsy Resource Image Archive Rabkin et. al. N Engl J Med 1997 Apr; 336:988-93.

  7. Novel herpes viral genome discovered in AIDS-KS tumor specimens in 1994 • Human herpes virus type 8 (HHV-8) or KSHV  targets spindle cell Chang et. al., Science 1994 Dec; 266:1865-9. www.aids-images.ch

  8. HHV-8 • Gamma herpesvirus. • Viral genes homologous to human genes • Tumorigenesis • Kaposi sarcoma • Multicentric Castleman’s disease • Primary effusion (body cavity) lymphoma (also EBV-associated) • Epidemiology (transmission, risk factors) still being worked out • HHV-8 viremia • 0-52% of KS patients viremic at any given time • Portends development of KS in several studies • HHV-8 in PBMC (not plasma) correlates with KS severity Casper, “HHV-8, KS & AIDS-associated Neoplasms.” Accessed www.hivinsite.com

  9. Global distribution of HHV-8 www.aids-images.ch

  10. Global distribution of KS Cancer Research UK www.info.cancerresearchuk.org/cancerstats

  11. Malignancies in Uganda:1982-2000 Kaharuza et. al. Int Conf AIDS 2004 Jul; 15: Abstract C11879.

  12. Clinical Features of KS • Wide spectrum of disease • Skin lesions • Brown, red, violaceous • Macules, papules, plaques, nodules • Differential Dx: • Bacillary angiomatosis • Pyogenic granuloma • Cutaneous manifestation of lymphoma • Angiosarcoma • Visceral involvement • GI tract (asymptomatic, abd pain, diarrhea, bleeding) • Pulmonary (asymptomatic, SOB, cough)  poor prognosis

  13. Courtesy of Dr. Virginia Broudy

  14. Courtesy of Dr. Virginia Broudy

  15. www.hivwebstudy.com www.idimages.org www.hab.hrsa.gov

  16. Staging of KS * >2 weeks of unexplained fever, night sweats, involuntary weight loss >10%, diarrhea AIDS Clinical Trial Group Krown et. al. J Clin Oncol 1997 Sep;15:3085-92.

  17. Survival with KS in HAART era Palmieri, et. al. HIV Medicine 2006 July; 7: 291-3.

  18. Treatment of KS • No universally effective therapy • Palliative. • Main indications are visceral disease, lymphedema & if KS bothers pt (e.g. symptomatic foot disease, facial lesions) • Tailor to individual patient • HAART • Local therapy • Radiation, cryotherapy, topical retinoids, intralesional chemo • Systemic chemotherapy • Liposomal anthracyclines (Doxil) – highest remission rates (60-80%) • Paclitaxel – partial remission seen in up to 60% • IFN-alfa – Response up to 40% Antman, et. al. N Engl J Med 2000 Apr; 342: 1027-38.

  19. Dual ART AZT introduced HAART introduced KS & HAART • Decline in incidence in US and Europe in era of HAART • One case series: 80% early stage lesions responded x 3-6 mo HAART • Madison Clinic data (HAART era): 37% KS improvement with 36 mo follow-up • Certain ARVs more effective vs. KS? Tx slide SEER Stat Database, www.seer.cancer.gov

  20. KS & Immune Reconstitution Inflammatory Syndrome • Immune Reconstitution Inflammatory Syndrome (IRIS) • Exuberant immune-mediated inflammatory response to antigenic triggers with start of HAART • Primary disorder = Immune perturbation not infection • Growing list of associated infectious & rheumatologic diseases • Case series n=9 patients with KS flare • Onset of flare – mean of 5 weeks into HAART (range, 3-7 wks) • Eruption of new lesions, increased edema/prominence of KS • Case of fatal KS-associated IRIS in a patient who presented with respiratory failure (negative BAL, steroid-responsive) Leidner, et. al. AIDS Patient Care STDs 2005 Oct;19: 635-44. Crane, et. al. Int J STD & AIDS 2005 Jan;16: 80-2.

  21. AIDS-associatedKaposi Sarcoma • Incidence high in pre-HAART era, now reduced but still common, esp. among MSM • KS prevalence mirrors prevalence of HHV-8 infection • Chronic disease without a cure, marked by slow often partial remission • Visceral disease, esp pulmonary involvement, associated with poor prognosis • HAART is probably key to KS treatment & should be initiated in all KS pts

  22. Case 2 47 yo journalist with stage 3 HIV with CD4 102 on HAART presents with fever, chills, diffuse abdominal pain, cough, bloody diarrhea. He returned from a recent trip to SE Asia. His exam is notable for HR 123 BP 90/45 RR 25 O2 Sat 93% on 3 L NC, petechial rash on trunk and scattered wheezing in all lung fields. CXR shows bilateral interstitial infiltrates. Bronchoscopy was performed. BAL revealed the following:

  23. What is your diagnosis?

  24. Disseminated Strongyloidiasis • Endemic in tropical or subtropical regions (SE Asia) • Strongyloides cause a systemic dissemination (hyperinfection syndrome) with high mortality in some patients, generally immunosuppressed (HIV+, chemo, steroids) • Intestinal invasion may result in gram negative sepsis • Trivia: what other conditions/meds predispose?

  25. Case 3 35 yo man with stage 3 HIV comes in c/o 3 weeks of HA, sleepiness and double vision. PMH: HIV dx 1990 – last CD4 50 in 2009 Hx depression with psychotic features Chronic hepatitis B Soc Hx: Immigrated from Somalia in 2008.

  26. Case 3 Exam: T 38.0 BP 140/85 HR 65 RR 14 GEN: Drowsy, thin man in no acute distress. Mental status: Opens eyes spontaneously, attends and able to answer questions appropriately, oriented to self, place and year. Obeys commands. NECK: No stiffness. NEURO: Cranial nerves II-XII intact & symmetric. Gait is wide-based. No focal impairment in sensory/motor exam. What would you do next?

  27. Lumbar puncture • Opening pressure 55 cm H2O • CSF WBC 153 (lymphocyte predominant) • CSF glucose 35 • CSF protein 87 CT head with contrast: No focal abnormalities.

  28. Tuberculous vs Cryptococcal Meningitis Cohen, CROI 2009, Abstract #791.

  29. Lumbar puncture • Opening pressure 55 cm H2O • CSF WBC 153 (lymphocyte predominant) • CSF glucose 35 • CSF protein 87 CSF Cryptococcal Antigen 1:512.

  30. Primary Induction Therapy for Cryptococcal Meningitis • Amphoterocin B deoxycholate 0.7-1.0 mg/kg or liposomal AmB 3-4 mg/kg or ABLC 5 mg/kg per day IV plus flucytosine (5-FC) 100 mg/kg/day x 2 weeks minimum OR • AmBd, liposomal AmB, ABLC plus fluconazole 800 mg x 2 wks minimum OR • Fluconazole ≥800 mg/day (1200 mg/day favored) plus 5FC 100 mg/kg/day x 6 weeks OR • Fluconazole 800-2000 mg/day; ≥1200 mg/day favored x 10-12 weeks if used alone Use of itraconazole is discouraged. 2010 Infectious Disease Society of America Guidelines

  31. RCT of Combination High-dose Fluconazole + 5FC vs Fluconazole alone Primary Outcome: Early fungicidal activity Secondary outcomes: 2-week, 10-week Mortality Nussbaum, Clin Infect Dis Feb 2010; 50:338-44.

  32. Nussbaum, Clin Infect Dis Feb 2010; 50:338-44.

  33. Case 3 35 yo man with stage 3 HIV comes in c/o 3 weeks of HA, sleepiness and double vision. PMH: HIV dx 1990 – last CD4 50 in 2009 Hx depression with psychotic features Chronic hepatitis B Soc Hx: Immigrated from Somalia in 2008. Medications: Efavirenz 600 mg PO qHS TDF + FTC 1 tab PO qDay

  34. Cryptococcal Meningitis & IRIS • Incidence 47 cases per 100 person-years • Median interval from HAART initiation to dx IRIS: 63 days (range, 12-129) • Headache is most common symptom; neck stiffness, photophobia, fever, focal neuro deficit less common • Papilledema & decreased LOC may be more common w/ CM-IRIS • OP higher at IRIS c/w first CM dx: median 46 vs 20 cm H2O • % PMN CSF higher in CM-IRIS; CrAg titers lower Sungkanuparph, Clin Infect Dis September 2009; 49:931-4.

  35. How soon can we start HAART in patients with Cryptococcal meningitis? Makadzange, Clin Infect Dis June 2010; 50:1532-38.

More Related